Valuation: Arrowhead Pharmaceuticals, Inc.

Market Cap 6.08B 5.52B 5.1B 4.6B 8.68B 568B 9.01B 61.41B 24.29B 306B 22.8B 22.32B 968B P/E 2027 *
-8.33x
P/E 2028 * -13.4x
Enterprise Value 5.72B 5.19B 4.8B 4.33B 8.17B 535B 8.48B 57.81B 22.87B 288B 21.47B 21.01B 911B EV / Sales 2027 *
18.2x
EV / Sales 2028 * 10.5x
Free-Float
94.57%
Yield 2027 *
-
Yield 2028 * -
1 day+0.78%
1 week-12.18%
Current month-27.63%
1 month-24.25%
3 months-50.68%
6 months-41.38%
Current year-34.70%
1 week 42.07
Extreme 42.07
48.99
1 month 42.07
Extreme 42.07
62
Current year 42.07
Extreme 42.07
95.49
1 year 37.06
Extreme 37.06
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2026-01-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Sell

Director

-2,000 0.0014%
8/18/26 Sell

Director

-11,600 0.0082%
6/15/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-12.18%+7.12%+50.00% 6.08B
-1.34%-4.12%+53.70%+68.83% 66.37B
+1.08%-1.26%+9.61%+91.79% 58.86B
+0.68%+0.54%+26.08%+86.79% 55.22B
-2.33%-4.07%+10.71%+114.45% 47.21B
-0.71%-6.95%+17.56%+24.43% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.85%-11.72%+126.01%+634.08% 35.19B
-0.17%-1.94%+82.25%+57.30% 32.66B
-1.43%-1.37%-40.93%+383.73% 26.73B
Average -0.77%-3.70%+30.68%+155.27% 41B
Weighted average by Cap. -0.78%-3.03%+32.97%+141.09%

Financials

2027 *2028 *
Net sales 315M 286M 264M 238M 449M 29.39B 466M 3.18B 1.26B 15.86B 1.18B 1.16B 50.11B 542M 492M 454M 410M 774M 50.61B 803M 5.47B 2.16B 27.31B 2.03B 1.99B 86.28B
Net income -742M -674M -622M -562M -1.06B -69.35B -1.1B -7.5B -2.97B -37.42B -2.78B -2.73B -118B -485M -440M -406M -367M -692M -45.28B -719M -4.9B -1.94B -24.43B -1.82B -1.78B -77.2B
Net Debt -356M -323M -299M -269M -508M -33.26B -528M -3.6B -1.42B -17.95B -1.34B -1.31B -56.7B -392M -356M -329M -297M -560M -36.64B -581M -3.96B -1.57B -19.77B -1.47B -1.44B -62.46B
Projected Income Statement - Annual - Arrowhead Pharmaceuticals, Inc.
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
1,062
Date Price Change Volume
26-11-18 US$43.41 +0.98% 427,196
26-11-17 US$42.99 -2.76% 3,703,616
26-11-16 US$44.21 -7.47% 1,863,749
26-11-13 US$47.78 +1.34% 3,113,499
26-11-12 US$47.15 -4.48% 2,164,345
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arrowhead Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
42.99USD
Average target price
105.86USD
Spread / Average Target
+146.24%
  1. Stock Market
  2. Stocks
  3. ARWR Stock